Relay Therapeutics (RLAY) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $4B
- As of Nov 13, 2026
- P/E
- -13.61x
- Trailing twelve months
- P/B
- 4.88x
- Latest reported equity
- P/S
- 400.00x
- Trailing twelve months
- ROE
- -35.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $4B
- As of Nov 13, 2026
- P/E
- -13.61x
- Trailing twelve months
- P/B
- 4.88x
- Latest reported equity
- P/S
- 400.00x
- Trailing twelve months
- ROE
- -35.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-13.61x
Net loss — not comparable
P/B
4.88x
P/S
400.00x
Earnings and dividend metrics▾
Earnings
EPS
-$1.33
Earnings per share
BPS
$3.71
Book value per share
ROE
-35.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $1.33 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.71 of net assets.
- ROE — shareholder equity shrank by 35.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Operating income decreased from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Operating income · same quarter, three years
Year-ago quarter -$80MDown
-$96M
Jul–Sep '24
-$80M
Jul–Sep '25
-$90M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Bergstrom Donald APresident, R&D · Oct 28, 2026Open-market sale2,252 shares · $42KAvg. price $18.62396,878 shares held after
- Catinazzo ThomasChief Financial Officer · Oct 28, 2026Open-market sale1,469 shares · $27KAvg. price $18.62103,665 shares held after
- Rahmer PeterSee remarks · Oct 28, 2026Open-market sale753 shares · $14KAvg. price $18.62222,904 shares held after
- Patel SanjivPresident and CEO · Oct 7, 2026Open-market sale48,199 shares · $872KAvg. price $18.1471,301 shares held after
- Catinazzo ThomasChief Financial Officer · Oct 6, 2026Open-market sale17,717 shares · $329KAvg. price $18.5879
Show 2 price lots
- 17,511 shares × $18.58$325K
- 206 shares × $19.26$4K
- Patel SanjivPresident and CEO · Sep 8, 2026Open-market sale48,199 shares · $913KAvg. price $18.94519,500 shares held after
- Catinazzo ThomasChief Financial Officer · Sep 8, 2026Open-market sale17,717 shares · $336KAvg. price $18.94122,851 shares held after
- Bergstrom Donald APresident, R&D · Sep 8, 2026Open-market sale8,530 shares · $162KAvg. price $18.97399,130 shares held after
- Rahmer PeterSee remarks · Aug 26, 2026Open-market sale4,508 shares · $90KAvg. price $20.03223,657 shares held after
- SVF Pauling (Cayman) Ltd10% owner · Aug 25, 2026Open-market sale6,000,000 shares · $116.4MAvg. price $19.421,904,963 shares held after
- Patel SanjivPresident and CEO · Aug 17, 2026Open-market sale48,199 shares · $980KAvg. price $20.33567,699 shares held after
- Catinazzo ThomasChief Financial Officer · Aug 14, 2026Open-market sale17,717 shares · $350KAvg. price $19.74140,568 shares held after
- Bergstrom Donald APresident, R&D · Jul 28, 2026Open-market sale2,237 shares · $42KAvg. price $18.61407,660 shares held after
- Catinazzo ThomasChief Financial Officer · Jul 28, 2026Open-market sale1,459 shares · $27KAvg. price $18.61158,285 shares held after
- Rahmer PeterSee remarks · Jul 28, 2026Open-market sale748 shares · $14KAvg. price $18.61228,165 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Relay Therapeutics (RLAY) stock information
NASDAQ
Relay Therapeutics (RLAY) is listed on NASDAQ. Its market capitalization is about $4B. On trailing-twelve-month earnings the P/E ratio is -13.61, and the P/B ratio is 4.88. Return on equity is -35.9%. These figures are computed in-house from official filings and are reference information only.
Relay Therapeutics — frequently asked questions
- What is the P/E ratio of Relay Therapeutics (RLAY)?
- On a trailing-twelve-month basis, RLAY trades at a P/E ratio of -13.61. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Relay Therapeutics?
- RLAY has a market capitalization of about $4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.